QQQ   430.57 (-0.11%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.82 (-1.80%)
BABA   69.92 (-0.99%)
T   16.00 (-1.48%)
F   12.14 (-0.74%)
MU   121.04 (-0.27%)
GE   155.38 (+1.09%)
CGC   6.84 (-2.01%)
DIS   113.72 (+0.68%)
AMC   2.88 (+16.60%)
PFE   25.76 (-0.58%)
PYPL   63.66 (+0.24%)
XOM   118.19 (-1.24%)
QQQ   430.57 (-0.11%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.82 (-1.80%)
BABA   69.92 (-0.99%)
T   16.00 (-1.48%)
F   12.14 (-0.74%)
MU   121.04 (-0.27%)
GE   155.38 (+1.09%)
CGC   6.84 (-2.01%)
DIS   113.72 (+0.68%)
AMC   2.88 (+16.60%)
PFE   25.76 (-0.58%)
PYPL   63.66 (+0.24%)
XOM   118.19 (-1.24%)
QQQ   430.57 (-0.11%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.82 (-1.80%)
BABA   69.92 (-0.99%)
T   16.00 (-1.48%)
F   12.14 (-0.74%)
MU   121.04 (-0.27%)
GE   155.38 (+1.09%)
CGC   6.84 (-2.01%)
DIS   113.72 (+0.68%)
AMC   2.88 (+16.60%)
PFE   25.76 (-0.58%)
PYPL   63.66 (+0.24%)
XOM   118.19 (-1.24%)
QQQ   430.57 (-0.11%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.82 (-1.80%)
BABA   69.92 (-0.99%)
T   16.00 (-1.48%)
F   12.14 (-0.74%)
MU   121.04 (-0.27%)
GE   155.38 (+1.09%)
CGC   6.84 (-2.01%)
DIS   113.72 (+0.68%)
AMC   2.88 (+16.60%)
PFE   25.76 (-0.58%)
PYPL   63.66 (+0.24%)
XOM   118.19 (-1.24%)

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

$230.61
-0.76 (-0.33%)
(As of 01:52 PM ET)
Today's Range
$222.90
$231.10
50-Day Range
$171.37
$283.23
52-Week Range
$119.76
$322.67
Volume
184,255 shs
Average Volume
529,973 shs
Market Capitalization
$4.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$377.40

Madrigal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
67.7% Upside
$377.40 Price Target
Short Interest
Bearish
16.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.60mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$31.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($21.48) to ($13.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Medical Sector

69th out of 930 stocks

Pharmaceutical Preparations Industry

21st out of 431 stocks

MDGL stock logo

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock Price History

MDGL Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
7 Stocks That Will Drive the Weight Loss Drugs Market (MDGL)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Madrigal Pharmaceuticals, Inc.
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/16/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
376
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$377.40
High Stock Price Target
$425.00
Low Stock Price Target
$270.00
Potential Upside/Downside
+63.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-373,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$20.53 per share

Miscellaneous

Free Float
15,138,000
Market Cap
$4.60 billion
Optionable
Optionable
Beta
-0.47

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 72)
    Founder, Chief Medical Officer, President of Research & Development and Director
    Comp: $939.83k
  • Mr. Brian J. Lynch J.D. (Age 62)
    Senior VP & General Counsel
    Comp: $763.75k
  • Mr. Alex G. Howarth (Age 55)
    Executive Officer
    Comp: $757.26k
  • Mr. William J. Sibold (Age 58)
    CEO, President & Director
  • Ms. Mardi C. Dier (Age 60)
    CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP
  • Mr. Ronald Filippo
    Chief Information Officer
  • Ms. Tina E. Ventura
    Chief Investor Relations Officer
  • Dr. Kianoush Motesharei Ph.d. (Age 54)
    Senior Vice President of Business & Corporate Development
  • Mr. Clint Wallace
    Chief Human Resources Officer
  • Mr. Edward Chiang
    Senior Vice President of Clinical & Technical Operations

MDGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price target for 2024?

10 equities research analysts have issued 12-month target prices for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $270.00 to $425.00. On average, they expect the company's share price to reach $377.40 in the next twelve months. This suggests a possible upside of 67.7% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2024?

Madrigal Pharmaceuticals' stock was trading at $231.38 at the beginning of the year. Since then, MDGL shares have decreased by 2.7% and is now trading at $225.05.
View the best growth stocks for 2024 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.26) by $0.42. During the same period in the previous year, the company earned ($4.98) EPS.

What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Rheos Capital Works Inc. (0.55%), Congress Park Capital LLC (0.01%) and Overbrook Management Corp (0.01%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, James M Daly, Paul A Friedman, Rebecca Taub, Remy Sukhija, Richard S Levy and Robert E Waltermire.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDGL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners